Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMSNASDAQ:BIVINASDAQ:CRVSNASDAQ:TYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/ABIVIBioVie$0.73-7.6%$1.28$0.62▼$7.50$13.29M0.641.75 million shs81,672 shsCRVSCorvus Pharmaceuticals$2.87-2.6%$4.16$1.30▼$10.00$193.17M0.71600,132 shs559,246 shsTYMETyme Technologies$0.31$0.30$0.22▼$1.14$53.51M0.931.01 million shs2.68 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BIVIBioVie+12.01%-16.73%-27.25%-66.40%+70.50%CRVSCorvus Pharmaceuticals+4.26%-8.41%-30.82%-47.96%+80.37%TYMETyme Technologies0.00%0.00%0.00%0.00%0.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABIVIBioVie2.2026 of 5 stars3.82.00.00.03.80.00.6CRVSCorvus Pharmaceuticals3.0958 of 5 stars3.63.00.00.04.02.50.6TYMETyme TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMSAdamas Pharmaceuticals 0.00N/AN/AN/ABIVIBioVie 3.50Strong Buy$3.00309.28% UpsideCRVSCorvus Pharmaceuticals 3.25Buy$15.67446.83% UpsideTYMETyme Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BIVI, CRVS, TYME, and ADMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$14.00 ➝ $15.003/26/2025CRVSCorvus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/18/2025BIVIBioVieBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/14/2025CRVSCorvus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 4/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMSAdamas Pharmaceuticals$74.46M5.05N/AN/A($0.47) per share-17.49BIVIBioVieN/AN/AN/AN/A$2.54 per shareN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.79 per shareN/ATYMETyme TechnologiesN/AN/AN/AN/A$0.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMSAdamas Pharmaceuticals-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/ABIVIBioVie-$32.12M-$9.76N/A∞N/AN/A-134.07%-93.44%5/13/2025 (Estimated)CRVSCorvus Pharmaceuticals-$27.03M-$0.97N/AN/AN/AN/A-70.71%-45.90%5/5/2025 (Estimated)TYMETyme Technologies-$23.63M-$0.14N/A∞N/AN/A-28.30%-26.21%N/ALatest BIVI, CRVS, TYME, and ADMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025CRVSCorvus Pharmaceuticals-$0.12N/AN/AN/AN/AN/A3/25/2025Q4 2024CRVSCorvus Pharmaceuticals-$0.12-$0.18-$0.06-$0.18N/AN/A2/11/2025Q1 2025BIVIBioVieN/A-$0.46N/A-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/ABIVIBioVieN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/ATYMETyme TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMSAdamas Pharmaceuticals21.254.534.17BIVIBioVieN/A16.9416.94CRVSCorvus PharmaceuticalsN/A0.920.92TYMETyme TechnologiesN/A14.0614.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMSAdamas Pharmaceuticals69.97%BIVIBioVie4.59%CRVSCorvus Pharmaceuticals46.64%TYMETyme Technologies16.69%Insider OwnershipCompanyInsider OwnershipADMSAdamas Pharmaceuticals18.90%BIVIBioVie4.00%CRVSCorvus Pharmaceuticals31.30%TYMETyme Technologies16.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMSAdamas Pharmaceuticals13845.79 million37.13 millionOptionableBIVIBioVie1018.45 million17.71 millionNo DataCRVSCorvus Pharmaceuticals3068.14 million44.15 millionOptionableTYMETyme Technologies17172.21 million143.10 millionOptionableBIVI, CRVS, TYME, and ADMS HeadlinesRecent News About These CompaniesTyme caps off a tough year for African startups with a unicorn crownJanuary 12, 2025 | independent.co.ugHow Nubank’s Investment in Tyme Helps African StartupsJanuary 8, 2025 | fintechmagazine.comNubank leads Tyme Group’s $250m Series D – valuing Tyme at $1.5bnJanuary 3, 2025 | intelligentcio.comTyme é avaliado em US$ 1,5 bi com apoio do Nubank, na ÁfricaDecember 18, 2024 | bloomberg.comBrazil’s Nubank invests $150 million in Tyme Group to expand digital banking offeringsDecember 18, 2024 | msn.comBrazilian bank Nubank makes a big R2.7bn investment in fintech Tyme GroupDecember 18, 2024 | msn.comSouth African Tyme Group Becomes Africa’s Latest Unicorn After $250M Series D FundingDecember 18, 2024 | msn.comTymeBank parent valued at $1.5-billion in latest fundraiseDecember 17, 2024 | techcentral.co.zaBrazilian fintech giant invests in SA-born Tyme GroupDecember 17, 2024 | itnewsafrica.comMulti-billion funding bolsters Tyme Group valuationDecember 17, 2024 | itweb.co.zaBillionaire Patrice Motsepe’s Tyme worth $1.5 billion becomes Africa’s 9th unicornDecember 17, 2024 | nairametrics.comTyme, Owners Of TymeBank And GoTyme, Raises R4.5 Billion In Funding Led By NYSE-Listed Brazilian FinTech NubankDecember 17, 2024 | techfinancials.co.zaBrazilian fintech Nubank’s $150mn investment to give South Africa’s Tyme unicorn statusDecember 17, 2024 | ft.comAfrican digital bank Tyme raises $250M round led by Nubank at $1.5B valuationDecember 17, 2024 | msn.comDigital bank Tyme gains unicorn status with $250m Series D raiseDecember 17, 2024 | finance.yahoo.comNubank Announces Investment in Tyme Group, a Digital Bank With Operations in South Africa and the PhilippinesDecember 16, 2024 | businesswire.comBest Restaurants in Leominster, MassachusettsNovember 10, 2024 | thetechedvocate.orgBest Restaurants in Quincy, IllinoisNovember 10, 2024 | thetechedvocate.orgBest Restaurants in Peoria, IllinoisNovember 9, 2024 | thetechedvocate.orgEden Green herb program named on TIME’s Best Inventions of 2024 listNovember 6, 2024 | producegrower.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIVI, CRVS, TYME, and ADMS Company DescriptionsAdamas Pharmaceuticals NASDAQ:ADMSAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.BioVie NASDAQ:BIVI$0.73 -0.06 (-7.57%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Corvus Pharmaceuticals NASDAQ:CRVS$2.86 -0.08 (-2.55%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Tyme Technologies NASDAQ:TYMETyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom's Big Outperformance Shows Strength Amid Tariff Decline Delta, Walmart Cut Profit Targets: Could Start Domino Effect Joby Aviation: Operational Momentum vs. Market Sentiment Carvana: Can Turnaround Strength Outdrive Market Headwinds? Is Alphabet a Generational Buying Opportunity at These Levels? Meta Seeks Trump's Help in FTC Trial: The Implications Are Huge Is Microsoft Stock Too Cheap to Ignore After Its Latest Drop? Harley-Davidson Tops Watchlists: Value Trap or Turnaround Play? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
